Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 1;12:619761. doi: 10.3389/fimmu.2021.619761

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 He, Fu, Zhou, Su, Gao, Zhang, Huang, Du and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CPT attenuates the inflammatory response in LPS-exposed BV-2 cells. (A) The viability of BV-2 cells was measured using CCK-8 assay. The cells were pretreated with CPT (0.5 μM and 1 μM) for 1 h and then treated with LPS (1 μg/mL) for 12 h (mRNA) and 24 h (protein). (B-H) The mRNA levels of M1 microglia markers (IL-6, TNF-α, iNOS, and COX-2) and M2 microglia markers (Ym-1, CD206, and Arg-1) were detected by RT-PCR. (I–P) The protein levels of M1 microglia markers and M2 microglia markers were measured using ELISA (IL-6 and TNF-α) and western blot (COX-2, iNOS, Arg-1, CD206, and Ym-1). Results are shown as means ± SD (n= 5). ^#p < 0.5 and ^##p < 0.01 vs. the no-treatment (NT) group; **p< 0.01 vs. the LPS-exposed group.